Moderna CEO: “We are now in a super exciting program where we inject mRNA in people’s heart after a heart attack to grow back new blood vessels and re-vascularize the heart”

Moderna CEO: “We are now in a super exciting program where we inject mRNA in people’s heart after a heart attack to grow back new blood vessels and re-vascularize the heart”

Time Stamp: January 11, 2023 4:49 PM
Source Node: 1891043

In April 2021, the Centers for Disease Control and Prevention (CDC) announced that “increased cases of myocarditis and pericarditis were reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna).”

The agency further stated that: “Data from multiple studies show a rare risk for myocarditis and/or pericarditis following receipt of mRNA COVID-19 vaccines. These rare cases of myocarditis or pericarditis have occurred most frequently in adolescent and young adult males, ages 16 years and older, within 7 days after receiving the second dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech and Moderna). There has not been a similar reporting pattern observed after receipt of the Janssen COVID-19 Vaccine (Johnson & Johnson).”

Fast forward almost two years later, there has been an increase in the number of reported cases of myocarditis. Epoch Times also reported that “a new peer-reviewed German Study also provides direct evidence of people died from mRNA-Vaccine-Damaged Hearts.”

With the number of myocarditis cases continuing to rise, Moderna CEO Stéphane Bancel announced a new mRNA shot to treat patients with heart failure. The announcement comes just three months after Bancel confirmed that Moderna would release a new mRNA ‘injection’ to repair heart muscles after a heart attack.

In an interview, Bancel said, “We are now in a super exciting program where we inject mRNA in people’s heart after a heart attack to grow back new blood vessels and re-vascularize the heart.”

During the interview, a Sky News reporter said there was an “irony” of the COVID-19 pandemic that has in some ways allowed companies like Moderna to “develop these other areas because of the revenues that came through the door.”

Reporter: “The irony of COVID is that is really has in some ways allowed you to go and develop these other areas because of the revenues that came through the door.”

Bancel agreed, saying: “You’re 100 percent right.”

Meanwhile, in a separate news release, Bancel said: “We enter 2023 in a great position, with significant momentum across our clinical pipeline, a highly energized team and a strong balance sheet of over $18 billion of cash and cash equivalents.”

Bancel added: “With our infectious disease franchise continuing to accelerate with exciting near-term catalysts for RSV Phase 3 data and Flu Phase 3 data, and recent breakthroughs in the development of individualized cancer treatments, as well as our rapid advancement in rare diseases and promising cardiology programs, the Moderna platform is delivering across several modalities. Our progress is meeting the high expectations we set out a few years ago, and with encouraging clinical data across the entire Moderna platform, we are accelerating our investments to deliver the greatest possible impact to people through mRNA medicines. Our board has approved a significant increase to our R&D investments, with a budget for 2023 of around $4.5 billion. 2023 is going to be a very exciting year for Moderna, and most importantly, for patients.”

Time Stamp:

More from TechStartups